The Brief
Health & Medicine 5 min read

From 70% to 82%: What a Personalised Cancer Vaccine Changes

NAVION

Share

A cancer vaccine tailored to each individual patient is expected to receive regulatory approval in the United States, Europe, and the United Kingdom next year. The vaccine targets melanoma, the most dangerous form of skin cancer, and works by training the immune system to recognise mutations that are unique to a specific person’s tumour. This is not a future possibility or an early-stage experiment. It has completed a late-stage clinical trial, and the results are now public.

How the Vaccine Actually Works

The process begins with genetic sequencing. A small sample of a patient’s cancer is sequenced and compared against the DNA found in that same person’s healthy blood cells. This comparison allows researchers to identify mutations that belong exclusively to the cancer, not to the patient’s normal biology.

From that analysis, the vaccine is constructed using mRNA technology, the same platform that underpinned the Covid-19 vaccines. The resulting injection encodes proteins corresponding to up to 34 of those cancer-specific mutations. Rebecca Lee at the University of Manchester describes it as a “fingerprint of proteins specifically associated with the cancer.” The goal is to help the immune system’s T-cells recognise and attack the tumour more effectively.

The vaccine is not used alone. In the trial, it was delivered alongside pembrolizumab, a standard immunotherapy drug that prevents T-cells from becoming exhausted once they begin attacking cancer cells. Both treatments were administered every three weeks for up to a year.

What the Trial Found

The trial enrolled more than 1,100 adults who had undergone surgery to remove high-risk melanomas, tumours considered likely to return or spread. Two-thirds received the personalised vaccine in addition to pembrolizumab. The remaining participants received a placebo alongside pembrolizumab.

Approximately two years after treatment began, 82 per cent of those who received the vaccine plus pembrolizumab were alive without cancer recurrence. Among those who received pembrolizumab alone, that figure was 70 per cent. Side effects were comparable between the two groups.

One important nuance: the trial measured a combined outcome that includes both recurrence and death. Alan Melcher at the Institute of Cancer Research in London notes that because a cancer must recur before it can cause death, this combined figure should be read primarily as evidence that the vaccine reduces recurrence. Whether it improves long-term survival rates is a question that will require more time. Those results, according to Lee, should be available within a few years.

The Cost Problem That Could Limit Access

Here is what most coverage of this result underplays. The vaccine’s effectiveness is not the primary obstacle to widespread use. The obstacle is economics.

Because the vaccine must be individually designed and manufactured for each patient, production is inherently expensive. A January report by Reuters suggested a cost of around $200,000 per treatment. Moderna and Merck, the two companies involved in the vaccine’s development, did not respond to requests about pricing.

In the UK, where 19,400 melanoma cases are diagnosed annually and roughly 25 per cent are classified as high risk, thousands of patients could theoretically benefit. Lee is direct about the tension: “If it was a cheap drug, I’d definitely say it will get approved [for NHS use], but it’s going to be expensive.” Regulatory approval and healthcare system adoption are two separate decisions, and the second one is where cost-effectiveness assessments become decisive.

This is a structural challenge that personalised medicine creates almost by definition. The more a treatment is tailored to an individual, the harder it becomes to manufacture at scale, and the harder it becomes to justify within systems designed around population-level cost calculations.

Why This Matters Beyond Melanoma

The significance of this trial extends past skin cancer. James Larkin, also at the Institute of Cancer Research, points out that personalised vaccines could potentially be applied to other cancers routinely treated with immunotherapy, including those affecting the lungs, bladder, and kidneys. That research is still ahead, and whether these vaccines could eventually function as standalone treatments rather than complements to existing immunotherapy is an open question.

What the melanoma trial establishes is a proof of concept for a broader shift in oncology: moving from treatments defined by where a cancer is located in the body to treatments defined by what a specific tumour’s mutations look like. That shift has been underway for years, but a late-stage trial of this scale, with results this clear, marks a meaningful step forward.

Melcher also raises a precision question that will shape how the vaccine is used in practice. Some patients may carry mutations that fail to trigger the expected immune response, or pembrolizumab alone may already be working so effectively that the vaccine adds little. Identifying biological markers that predict who will benefit most is the next research priority.

In Short

A personalised mRNA vaccine for high-risk melanoma has shown a meaningful improvement in preventing cancer recurrence in a large late-stage trial, with 82 per cent of vaccinated patients remaining cancer-free at two years compared to 70 per cent on standard treatment alone. Regulatory approval in the US, Europe, and UK is expected next year. The deeper story is not the science, which is compelling, but the economics: a treatment costing around $200,000 per patient, built on a manufacturing process that cannot easily scale, will face serious scrutiny from health systems before it reaches patients. The technology works. The harder problem is who gets access to it.

Based on reporting from New Scientist.

Written by

NAVION